Science

Brain Health

Rose Hill has been working diligently to produce, analyze and utilize as many species as possible and genetics of psychedelic mushrooms for almost a decade. Our team of mycologists and partners have been developing methods to improve the cultivation and harvesting of these genetics in a wide array of environments.

PTSD

U.S. Census Bureau, there were around 16.5 million veterans in the United States in 2021. About 5 out of every 100 adults (or 5%) in the U.S. has PTSD in any given year. In 2020, about 13 million Americans had PTSD. Women are more likely to develop PTSD than men. About 8 of every 100 women (or 8%) and 4 of every 100 men (or 4%) will have PTSD at some point in their life. There are potentially 825,000 US Veterans with PTSD.

Psilocybin, the active ingredient in magic mushrooms, has been investigated for its potential use in the treatment of post-traumatic stress disorder (PTSD). Studies have suggested that psilocybin can reduce the symptoms of PTSD, such as anxiety and depression, by promoting neuroplasticity and fostering new neural connections in the brain.

Autism

Some studies have suggested that the serotonin system, including serotonin transporters and receptors, differs between autistic and non-autistic individuals. To study this relationship further, COMPASS Pathways this year announced an investigator-initiated study using its patented formulation of synthetic psilocybin, COMP360, to investigate how the serotonin system may work differently in autistic and non-autistic adults.

Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms. It has been used for thousands of years by indigenous cultures for medicinal and spiritual purposes. Recently, there has been growing interest in the potential therapeutic benefits of psilocybin for various mental health conditions, including autism.

Stroke

Recent research has explored the potential therapeutic effects of psilocybin on individuals recovering from strokes. A mini-review incorporating in vitro, in vivo, and clinical studies focused on classical psychedelics, including psilocybin, has indicated four significant ways in which these substances may contribute to post-stroke recovery.

Depression

Studies have increasingly highlighted the promise of psilocybin, a naturally occurring psychedelic compound, as a potential therapy for treatment-resistant depression. The compound has demonstrated efficacy in cases where conventional antidepressants have yielded limited success. In a study involving 233 patients who had previously tried at least two antidepressants without significant improvement, psilocybin was administered, revealing its potential benefits for individuals grappling with hard-to-treat depression.

Genetics

At Rose Hill, we are at the forefront of scientific advancement in the field of psilocybin research, boasting a comprehensive library of over 50 distinct genetic strains. Our team is dedicated and always looking enhance cultivation processes, focusing on genetics that yield higher potency, increased stability, and greater overall output. This relentless pursuit of excellence in genetic development not only sets us apart but also significantly contributes to the broader scientific understanding of psilocybin’s potential.

Standardization

At Rose Hill, we’re dedicated to refining the cultivation process of P. cubensis mushrooms to ensure a consistent and reliable product. We’re conducting studies to compare the chemical composition of mushrooms grown in a commercial setting in Jamaica with those grown under controlled conditions at the University of Guelph. The goal is to create a standard in cultivating psychedelic mushrooms that guarantees the same high quality and potency, regardless of where they are grown. This research is key to our commitment to providing dependable and effective mushrooms for both research purposes and therapeutic applications.

Analytics

Rose Hill is committed to precise and trustworthy testing practices, ensuring our psilocybin products meet the highest standards of quality and safety. Each of our unique genetic strains undergoes thorough analysis, which includes a full panel certificate of analysis to identify and measure various compounds. Our analysis includes, but is not limited to, Psilocybin, Psilocin, Baeocystin, Norbaeocystin, Norpsilocin, Aeruginascin, 4-hydroxy TMT, Harmine, and Harmane, ensuring a comprehensive understanding of the composition of each sample.

Test Results

Psilocybe cubensis

Old Dirty PE 1-P1

View test result

Psilocybe cubensis

Sacred Sun 2-P2

View test result

Psilocybe cubensis

Hawaiian 3-P3

View test result

Psilocybe cubensis

Blue Meanie 4-P4

View test result

Psilocybe cubensis

DC Mak 5-P5

View test result